MediWound (MDWD) Scheduled to Post Quarterly Earnings on Wednesday

MediWound (NASDAQ:MDWD) will release its earnings data before the market opens on Wednesday, August 14th. Analysts expect MediWound to post earnings of ($0.42) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. MediWound had a negative net margin of 64.24% and a negative return on equity of 21.67%. The business had revenue of $4.96 million for the quarter, compared to analysts’ expectations of $4.65 million. On average, analysts expect MediWound to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MediWound Stock Down 0.6 %

Shares of MDWD stock opened at $17.95 on Tuesday. The business has a fifty day simple moving average of $17.32 and a 200 day simple moving average of $16.14. MediWound has a twelve month low of $7.10 and a twelve month high of $24.00. The company has a market cap of $166.65 million, a P/E ratio of -12.91 and a beta of 0.81.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Maxim Group raised their target price on shares of MediWound from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of MediWound in a report on Tuesday, July 16th. Finally, StockNews.com upgraded MediWound to a “sell” rating in a research report on Monday, August 5th.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.